Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 7/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354664 | 0.87 | CTSK (0.48) | EPHX2CASRPOLBCTDSP1MEN1 | |
| SCHEMBL8354345 | 0.85 | EPHX2 (0.50) | EPHX2CASRPOLBCTDSP1MEN1 | |
| Hydrochloric Acid SCHEMBL4815550 | 0.84 | EPHX2 (0.49) | EPHX2CASRPOLBCTDSP1MEN1 | |
| SCHEMBL4897025 | 0.83 | POLB (0.46) | EPHX2CASRPOLBCTDSP1MEN1 | |
| SCHEMBL4904605 | 0.83 | POLB (0.44) | EPHX2CASRPOLBCTDSP1MEN1 | |
| SCHEMBL4814646 | 0.82 | POLB (0.50) | CASRPOLBCTDSP1MEN1KMT2A | |
| SCHEMBL4814666 | 0.82 | POLB (0.50) | CASRPOLBCTDSP1MEN1KMT2A | |
| SCHEMBL4820525 | 0.82 | POLB (0.67) | POLBCTDSP1MEN1KMT2ACTSK | |
| SCHEMBL5639478 | 0.82 | POLB (0.67) | POLBCTDSP1MEN1KMT2ACTSK | |
| SCHEMBL4820530 | 0.82 | POLB (0.67) | POLBCTDSP1MEN1KMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | EPHX2 2447/4885CASR 2818/4885POLB 2328/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | EPHX2 2408/4885CASR 1463/4885POLB 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.